Early Stage Cancer CTCs Indicators of Poor Prognosis
By LabMedica International staff writers Posted on 12 Sep 2017 |
Image: A colored scanning electron micrograph (SEM) of a lung cancer cell during cell division (Photo courtesy of the National Institutes of Health).
By testing blood from a pulmonary vein near the site of a lung tumor rather than from a peripheral vein, cancer researchers found that the presence of circulating tumor cells (CTCs) in the blood during early stages of the disease was indicative of a poor prognosis for the patient.
Due to the limited CTC numbers in peripheral blood in early stages, investigators at the University of Michigan (Ann Arbor, USA) examined the CTCs in pulmonary vein blood accessed during surgical resection of tumors. Pulmonary vein (PV) and peripheral vein (Pe) blood specimens from patients with lung cancer were drawn during surgery and assessed for CTC burden using a microfluidic device.
From 108 blood samples analyzed from 36 patients, PV had significantly higher number of CTCs compared to pre-operative Pe and intra-operative Pe blood. CTC clusters with large number of CTCs were observed in 50% of patients, with PV often revealing larger clusters. Long-term surveillance indicated that presence of clusters in pre-operative Pe blood predicted a trend toward poor prognosis.
Gene ontology analysis revealed enrichment of cell migration and immune-related pathways in CTC clusters, suggesting survival advantage of clusters in circulation. Clusters displayed characteristics of therapeutic resistance, indicating the aggressive nature of these cells. Thus, CTCs isolated from early stages of lung cancer were predictive of poor prognosis and could be analyzed to determine biomarkers predictive of recurrence.
"The tumors were constantly shedding cells even when they were small—that's one thing we learned," said senior author Dr. Sunitha Nagrath, professor of chemical engineering at the University of Michigan. "Although we define the tumors as early stage, already they are disseminating cells in the body. Even though you removed the tumor, you left behind these hundreds and hundreds of cells. If you know this patient walking out of the clinic is going to relapse after less than a year because of these cells, why don't we treat them now?"
The study was published in the July 17, 2017, online edition of the journal Cancer Research.
Related Links:
University of Michigan
Due to the limited CTC numbers in peripheral blood in early stages, investigators at the University of Michigan (Ann Arbor, USA) examined the CTCs in pulmonary vein blood accessed during surgical resection of tumors. Pulmonary vein (PV) and peripheral vein (Pe) blood specimens from patients with lung cancer were drawn during surgery and assessed for CTC burden using a microfluidic device.
From 108 blood samples analyzed from 36 patients, PV had significantly higher number of CTCs compared to pre-operative Pe and intra-operative Pe blood. CTC clusters with large number of CTCs were observed in 50% of patients, with PV often revealing larger clusters. Long-term surveillance indicated that presence of clusters in pre-operative Pe blood predicted a trend toward poor prognosis.
Gene ontology analysis revealed enrichment of cell migration and immune-related pathways in CTC clusters, suggesting survival advantage of clusters in circulation. Clusters displayed characteristics of therapeutic resistance, indicating the aggressive nature of these cells. Thus, CTCs isolated from early stages of lung cancer were predictive of poor prognosis and could be analyzed to determine biomarkers predictive of recurrence.
"The tumors were constantly shedding cells even when they were small—that's one thing we learned," said senior author Dr. Sunitha Nagrath, professor of chemical engineering at the University of Michigan. "Although we define the tumors as early stage, already they are disseminating cells in the body. Even though you removed the tumor, you left behind these hundreds and hundreds of cells. If you know this patient walking out of the clinic is going to relapse after less than a year because of these cells, why don't we treat them now?"
The study was published in the July 17, 2017, online edition of the journal Cancer Research.
Related Links:
University of Michigan
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders